Canan Alhan

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Theresia M. Westers, Robin Ireland, Wolfgang Kern et al. · Leukemia · 2012 · 243 citations · Full text

Hematological Malignancy, Flow Cytometry, Myelodysplastic Syndromes +12

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Arjan A. van de Loosdrecht, Canan Alhan, Marie C. Béné et al. · Haematologica · 2009 · 236 citations · Full text

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study

Matteo Giovanni Della Porta, Cristina Picone, Cristiana Pascutto et al. · Haematologica · 2012 · 165 citations · Full text

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans et al. · British Journal of Haematology · 2011 · 106 citations · Full text

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Theresia M. Westers, Canan Alhan, Martine E.D. Chamuleau et al. · Blood · 2009 · 91 citations